Aim: To critically appraise and evaluate the evidence for effectiveness of curcuminoids in the treatment of osteoarthritis (OA) in adults.
Several dietary supplements are being marketed as treatment aids for OA, but the evidence for their effectiveness and safety remains uncertain. 7 One such group of supplements currently promoted are the curcuminoids.
The curcuminoids are primarily components of the culinary spice plant, Curcuma longa (turmeric), the extracts of which are used as condiments and flavoring in the food industry. 8 Biochemically, the curcuminoids comprise curcumin, demethoxycurcumin (DMC) and bisdemethoxycurcumin (BDMC), 9 and in soluble form generally exist as keto-enol tautomers. 10 Pharmacologically, curcuminoids have been reported to possess significant anti-inflammatory properties. 11 In vitro studies have shown that curcuminoids exert anti-apoptotic actions on interleukin (IL)-1b-stimulated human articular chondrocytes. 12, 13 Laboratory models have demonstrated that curcuminoids inhibit pro-inflammatory mediators, including prostaglandin (PG)E2, nitric oxide, IL-6 and IL-8 in bovine chondrocytes. 14, 15 In human chondrocytes, curcuminoids have been shown to inhibit the action of pro-inflammatory mediators and also inhibit the production of metalloproteinase-3. 16 Curcuminoids have also been reported to exhibit antioxidant properties. 17 They have been demonstrated to scavenge reactive oxygen and nitrogen species [18] [19] [20] and inhibit the activity of IL-1b-induced superoxide dismutase. 21 In vitro studies have also shown that curcuminoids inhibit IL-1b-induced glycosaminoglycan (GAG) release from animal and human OA cartilage explants. 22, 23 Randomized clinical trials (RCTs) in animals have suggested that Curcuma extracts (comprised of mixtures of Indian and Javanese turmeric with essential oils) may have beneficial effects in treatment of OA 24 and results of a recent large observational study including 820 adults with painful OA showed evidence of benefits with curcuminoids in real-life clinical practice. 25 Several clinical trials investigating the effect of curcuminoids in OA have also been published. However, the evidence for effectiveness of curcuminoids in OA management is not established. Therefore, the objective of this review was to critically appraise and evaluate the evidence for effectiveness of curcuminoids in the treatment of OA, using the data from published RCTs in adults.
MATERIALS AND METHODS
We conducted electronic searches in the following databases: Medline, Embase, AMED, Cinahl, the Cochrane library and the ISI Web of Science. Each database was searched from inception till March 2015 (the searches were updated in November 2016). No time or language restrictions were imposed. We also searched for ongoing clinical trials on ClinicalTrials.gov (http://clinicaltri als.gov), and the WHO's International Clinical Trials Registry Platform (ICTRP) (http://www.who.int/ictrp/ search/en/) (see Appendix S1 for a comprehensive search strategy). A reference management system (EndNoteX4) was used to identify and remove duplicate studies. We conducted hand searches of the bibliographies of the retrieved full texts of relevant studies. Where necessary, we requested additional information from study authors.
We only included RCTs which assessed the effectiveness of orally administered curcuminoids in OA in adults at least 40 years old. Included studies also had to last at least 4 weeks in duration and must have reported OA outcome measures. Studies containing more than one intervention arm were included if a trial arm with a curcuminoid-only intervention compared with a placebo, standard care or no intervention group, for which comparative results could be extracted. We excluded studies in which curcuminoids were combined with other types of interventions.
Primary outcomes were pain, physical function and quality of life (QoL). Secondary outcomes included use of rescue medication, adverse events and drop-out rates. The risk of bias for included studies was assessed using the Cochrane risk of bias criteria 26 which examines the following domains:
• method of randomization • concealment of allocation • blinding of participants and personnel • blinding of outcome assessment • incomplete outcome data • selective reporting and • other biases (e.g., industry funding, conflicts of interest, etc.).
Two reviewers (IJO and EAS) independently assessed the risk of bias for included studies. Disagreements were resolved via consensus. If consensus could not be reached, a third reviewer (CJH) arbitrated. We extracted the following from included studies: study ID (author, publication year, journal,) participants (numbers, duration and severity of OA, setting and method of OA diagnosis, demographics, etc.), intervention (type of intervention and duration), results (primary and secondary outcome measures, effect size, statistical significance, adverse effects) and sources of funding.
Based on pre-to post-intervention changes, we computed mean differences (MD) and 95% confidence intervals (CI) for continuous outcomes and risk ratios (RR) with 95% CI for dichotomous outcomes, using standard meta-analysis software (RevMan 5.3). 27 Where the scales of the components of outcome measures varied between pooled data, standardized mean differences (SMD) were used instead of MD to compute effect measures. We used the random-effects model for meta-analyses and tested the robustness of the overall analyses using sensitivity analyses (by analyzing trials based on reporting quality, dosage of curcuminoids, or duration of intervention). We planned to carry out subgroup analyses by assessing the difference between groups in trials based on participant characteristics -age, gender, severity of OA or site of OA. We investigated heterogeneity using the I 2 statistic; values of 25%, 50% and 75% indicated low, medium and high statistical heterogeneity, respectively. We planned to test for publication bias using a funnel plot; however, because < 10 studies were included this was not possible. One reviewer (IJO) entered data into RevMan 5 software for statistical pooling, while a second reviewer (EAS) independently crosschecked data entry. Disagreements were resolved through discussion. Where we were unable to statistically pool data, the results were presented in a narrative fashion. We used dose-effect plots to explore the relationships between curcuminoids and OA outcomes.
RESULTS
Our electronic searches returned 370 non-duplicate citations, out of which 19 full-text articles (including two abstracts) were assessed for eligibility (Fig. 1) . We excluded seven studies because curcuminoids were combined with other types of intervention, [28] [29] [30] [31] [32] [33] [34] [35] one study because it included participants with rheumatoid arthritis 36 and another because curcuminoid was used as an add-on to conventional treatment. 37 We also excluded one study because there was no relevant outcome 38 and one (abstract) because it was a duplicate of another excluded study. 39 Finally, we included seven studies [40] [41] [42] [43] [44] [45] [46] with a total of 797 participants. Key details of the included studies are shown in Table 1 .
All the studies were conducted in Asia and included participants with primary knee OA ( Table 1) . In four studies the proportion of participants with bilateral knee OA ranged from 37% 44 to 100%. 45 Three studies 42, 43, 46 did not report the proportion of participants with bilateral knee OA. The mean age of the participants ranged from 57 to 69 years, and the duration of intervention was between 4 and 16 weeks. The duration of symptoms was approximately 20 months in one study 40 and 12 months in another 41 ; a third study 42 included participants with at least 6 months duration of symptoms. Four studies [43] [44] [45] [46] did not report the duration of OA symptoms for their study participants. There were no significant differences in baseline characteristics of participants between the intervention and control groups (Table S1 ). Two studies used the American Rheumatism Association criteria for diagnosis of OA; three used radiological evidence; and two used the American College of Rheumatology (ACR) criteria (one of these also used personal report of pain by participants). The overall severity of OA across the studies was mild to moderate (Table 1) .
Six studies used one or more validated tools for pain assessment (Table 1 ). Five assessed pain using the Western Ontario and McMaster Universities Arthritis Index (WOMAC) criteria, five used a visual assessment scale (VAS), and one study 44 used the Japanese Knee Osteoarthritis Measure (JKOM) and the knee scoring system of the Japanese Orthopedic Association (JOA). In one study, 40 the assessment tool was the 0-10 point numerical rating scale (NRS). Five studies used validated tools (either WOMAC or JOA) to assess overall global function. QoL was assessed using the Lequesne pain-function index (LPFI). There were variations in the components of some of the outcome measures for the included studies (see Table S1 for full description of outcome measures and components).
The daily dose of curcuminoids varied from 180 mg to 2 g daily ( Table 1 ). There were variations in the techniques used to solubilize and enhance the bioavailability of curcuminoids across the studies. Three studies 40, 41, 46 used similar methods to extract curcuminoids; however, the concentration of pure curcumin was between 75% and 85% in two studies, 40, 41 while the concentration was reported as ≥ 95% in the third. 46 One study 42 used polysaccharide to enhance the bioavailability of curcuminoids, another 45 combined curcuminoids with Bioperineâ to enhance bioavailability, while another 44 used surface-controlled water-dispersible curcumin to increase the bioavailability. The method used to extract curcuminoids in one study 43 was unclear.
Five studies [42] [43] [44] [45] [46] used a placebo as comparator, while ibuprofen was used as the comparator in two studies. 40, 41 Rescue medications used were tramadol, 41 acetaminophen, 42 celecoxib or pain relief patches 44 and naproxen. 45 In one study, 46 participants were administered diclofenac with omeprazole as co-intervention. In one study, 40 participants did not use rescue medication, while it was unclear whether rescue medications were administered in another. 43 Five studies [40] [41] [42] 44, 45 used pill count to monitor compliance. Three studies 40, 41, 45 were funded by public institutions, two by manufacturers, 44, 46 one study 42 did not specify the funding and it was unclear whether there was any funding in one study 43 (Table 1) . Three studies [40] [41] [42] had low risk of both random sequence generation and allocation concealment and three 41, 44, 45 showed low risk of selection bias (Fig. 2 ). One study 40 had a high risk of performance bias because the interventions were open-label. Three studies [40] [41] [42] adequately reported blinding of outcome assessment and incomplete outcome data and five 40, 41, [44] [45] [46] showed low risk of selective reporting bias. Four studies showed unclear risk of other biases, while three showed high risk of other biases due to discrepancy in the frequency of daily interventions between groups, 40 significant difference in the proportion of participants on NSAIDs at baseline between groups 42 and failure to specify daily dosages of use of NSAIDs at baseline. 45 
Effect of curcuminoids on knee pain
One study 40 (n = 107) reported there was no significant difference in the mean NRS pain scores on level walking between curcuminoids and ibuprofen, MD 0.67 (95% CI: 0.35-1.68, P = 0.20); there was also no significant difference on climbing stairs in mean NRS pain scores À0.06 (95% CI: À1.07 to 0.96; P = 0.92).
Three studies (n = 531) reported adequate data for pain using the WOMAC pain score (a subscale of WOMAC total score). There was no significant effect with curcuminoids compared with controls, SMD: À0.80 (95% CI: À2.08 to 0.48; I 2 = 97%; P = 0.22; Table 2 ).
Five studies (n = 366) reported pain scores using VAS; the studies all had placebo as comparator. Figure 3 shows there was a significant reduction in pain with curcuminoids compared with placebo, SMD: À3.30 (95% CI: À4.99 to À2.01; I 2 = 95%; P < 0.00001). A dose-effect plot revealed a significant relationship between increased doses of curcuminoid and pain reduction (R = 0.89, P = 0.02; Fig. S1 ). Metaanalysis of three (n = 258) that used the same VAS scale showed a significant reduction in VAS scores favoring the curcuminoids, MD: À3.91 (95% CI: À5.30 to À2.52; I 2 = 88%; P < 0.00001; Table 2 ). Further analyses of two studies (n = 227) with similar daily dosages showed direction of results, with some reduction in heterogeneity, MD: À4.15 (95% CI: À5.12 to À3.18; I 2 =70%; P < 0.00001).
Effect of curcuminoids on physical function
In one study, 40 there was no significant difference in time spent on 100-m walk, MD: 5.07 s (95% CI: À2.09 to 12.23, P = 0.16) or the time spent going up and down a flight of stairs, MD: 2.75 s (95% CI: À0.50 to 5.99; P = 0.10) between curcuminoids and ibuprofen. In another study, 42 there was a significant reduction in the number of patients complaining of joint tenderness with curcuminoids compared with placebo (86.2% vs. 16.7%, P < 0.01).
Three studies (n = 531) reported adequate data using the WOMAC function score (a subscale of WOMAC total score). There was a significant improvement favoring curcuminoids over controls, SMD: À1.84 (95% CI: À3.54 to À0.13; I 2 = 98%; P = 0.04; Table 2 ). Sensitivity analysis showed that curcuminoids were significantly more effective than placebo, but significantly less effective compared with ibuprofen.
There was no significant difference in WOMAC stiffness scores between curcuminoids and controls, SMD: À0.10 (95% CI: À1.08 to 1.29; I 2 = 97%; P = 0.86; Table 2 ); however, sensitivity analyses showed that the curcuminoids were significantly less effective at improving stiffness symptoms compared with ibuprofen, but significantly more effective when compared with placebo (Fig. S2) .
Effect of curcuminoids on overall (global) function
One study 42 reported a significant reduction in Clinicians Global Impression of Change (CGIC) with curcuminoids compared with placebo, mean CGIC score À2.92 (SD: 0.64) versus À1.05 (SD: 0.05); P < 0.05; Table S1 ). Another study 43 reported a significant improvement in the mean patient global assessment scores in favor of curcuminoids compared with placebo, 3.1 (SD: 1.0) versus 2.4 (SD: 0.9), P = 0.04; however, there was no significant difference in mean physician global assessment scores (actual and P-values not reported).
Four studies (n = 498) reported adequate data for WOMAC total score (i.e., pain, stiffness and function). Meta-analysis showed a significant reduction in favor of curcuminoids, SMD: À3.29 (95% CI: À6.23 to À0.35; P = 0.03; I 2 = 99%; Fig. 4 ). Sensitivity analysis including RCTs with similar study design showed similar results, with some reduction in heterogeneity, SMD: À3.18 (95% CI: À4.25 to À2.11; I 2 = 67%; P < 00001). Where the components of outcome measures varied across studies for pooled data, SMDs were used as effect estimates. Due to insufficient data, we were unable to conduct subgroup analyses. ‡ Contains domains of pain, function and activities of daily living. 95% CI, 95% confidence interval; MD, mean difference; RCT, randomized controlled trial; RR, risk ratio; SMD, standardized mean difference; WOMAC, Western Ontario and McMaster Universities Arthritis Index.
Effect of curcuminoids on QoL
Two studies (n = 107) reported adequate data for statistical pooling using the LPFI scores. There was a significant increase in LPFI scores favoring curcuminoids compared with placebo, MD: À2.69 (95% CI: À3.48 to À1.90; I 2 = 0%; P < 0.00001; Table 2 ).
Effect of curcuminoids on use of rescue medication
Four studies (n = 567) reported adequate data for statistical pooling. There was a significant reduction with use of rescue medication favoring curcuminoids over controls, RR: 0.52 (95% CI: 0.29-0.90; I 2 = 50%; P = 0.02; Table 2 ; Fig. S3 ).
Frequency of adverse events with curcuminoids
Five studies (n = 727) reported the incidence of adverse events with curcuminoid use. There was no significant difference in the frequency of adverse events between curcuminoids and controls, RR: 0.84 (95% CI: 0.66-1.08; I 2 = 0%; P = 0.17; Table 2 ). Sensitivity analysis showed no significant difference between curcuminoids and ibuprofen, RR: 0.81 (95% CI: 0.63-1.05; I 2 = 0%; P = 0.11). In one study, 41 the frequency of abdominal pain/distension was significantly lower with curcuminoids compared with ibuprofen (10.8% vs. 18.1%, P = 0.046).
Withdrawal rates
There was no significant difference in the rates of lossto-follow-up across the six studies that reported data, RR: 0.93 (95% CI: 0.62-1.41; I 2 = 13%; P = 0.75; P = 0.92; Table 2 ). In total 103 drop-outs were reported across the six studies.
Adherence and compliance
One study 40 reported significantly better compliance rates with curcuminoids compared with ibuprofen (90.1% vs. 82.8%, P = 0.001). A second study reported no significant difference in compliance rates between curcuminoids and ibuprofen (93.8% vs. 92.6%, P = 0.202). One study 44 reported similar rates of medication compliance for both intervention and controls. Four studies 42, 43, 45, 46 did not report the compliance rates of study participants.
DISCUSSION
The results of our meta-analysis indicate that curcuminoids significantly reduce VAS pain scores in knee compared with placebo, but have significantly less painrelieving effect (WOMAC) in comparison with ibuprofen. The meta-analysis shows that curcuminoids are as effective as ibuprofen on WOMAC global function scores in OA and significantly more effective than placebo. Supplementation with curcuminoids also results in significant improvements in LPFI QoL scores and WOMAC joint stiffness scores compared with placebo, and a reduction in the use of concomitant medication in knee OA patients. In addition, curcuminoids are significantly more effective than placebo, but significantly less effective than ibuprofen at improving WOMAC physical function scores. The meta-analytic results should be interpreted with caution because of the high heterogeneity observed in some of the analyses. Our results support the results of a previous review which concluded that curcuminoids are as effective as ibuprofen in the treatment of OA. 47 In contrast to that report, our review included at least four studies that were not available for inclusion in the review, included only studies with curcuminoids as sole supplement, and statistically combined data. Our results also corroborate the conclusions of two recent reviews which suggested beneficial effects of curcuminoids in the treatment of OA. 48, 49 In contrast to those reports, we used SMDs rather than MDs to account for variations in outcome measures across the studies, explored dose-effect relationships, and included one new trial 46 which was not available for those reviews.
The heterogeneity observed in the meta-analytic results may have resulted from variation in the reporting quality across the RCTs, differences in the demographic characteristics of study participants, differences in the durations of intervention, and variation in daily dosages and bioavailability of curcuminoids and types of control interventions. The results of sensitivity analyses were generally associated with marked reductions in heterogeneity, and confirm the trueness of overall findings. However, the trueness of the effect is debatable.
Our findings are consistent with the results of an RCT of 80 participants with knee OA which demonstrated that curcuminoids have comparable levels of effectiveness with diclofenac sodium at reducing the secretion of cyclo-oxygenase 2 (COX-2) in synovial fluid monocytes. 50 This indicates that the pharmacologic action of the curcuminoids mimics those of the COX-2 inhibitors, and may be useful adjuncts in management of OA and other pain conditions. Whether this action of the curcuminoids can be utilized in preventive or early management of OA is unknown and warrants further investigation.
Our meta-analytic results showed that curcuminoids have beneficial effects on QoL scores in patients with knee OA. The findings are consistent with the results of a large observational study which demonstrated that curcuminoids use is associated with significant improvements in QoL. 25 In addition, the significant reduction in the need for rescue medication with curcuminoids compared with placebo suggests that their usage could lead to fewer disruptions in daily activities. However, most of the trials had small sample sizes and this could have distorted our meta-analytic results. 51 Our results showed that curcuminoids are ineffective at alleviating stiffness. Knee stiffness has important clinical implications in OA; its presence indicates an increased risk of progression of the disease over time. 52 The incongruence between our meta-analysis results and the results of two studies which did not provide adequate data for statistical pooling may have been due to the fact that stiffness is not sufficiently assessed in knee OA questionnaires. Of the 24-item components in the WOMAC assessment scale, 53 only two relate to stiffness. Indeed the test-retest reliability of the WOMAC stiffness subscale has been reported as low. 54 Furthermore, self-reported stiffness has been reported to poorly correlate with walking stiffness. 55 However, the significant improvement observed with ibuprofen compared with curcuminoids coupled with the low heterogeneity suggests that curcuminoids have no benefit on knee stiffness in OA.
While the dose-effect plots showed a significant relationship for VAS score, only five studies were included in the analysis and they all had small sample sizes. Whether the relationship observed in the plot is valid is uncertain as the educational or social status of the included participants was not reported in any of the studies; VAS scores have been shown to be significantly more reliable in literates compared with illiterates. 56 Furthermore, inadequate data prevented us from exploring dose-effect relationships for several other outcomes; this is compounded by the variations in the methods used to increase bioavailability of the product across the studies. These drawbacks indicate that the minimum effective dose for curcuminoids is not established. Curcuminoids appear to be well tolerated, and have less frequent adverse events compared with ibuprofen (and possibly other NSAIDs). However, the short duration of the RCTs does not allow for a longterm evaluation of its safety profile. Nevertheless, the safety of oral or dietary curcuminoids has been demonstrated in an 8-month study involving 100 participants with OA. 37 Because curcuminoids are poorly absorbed orally, 57 the studies included in our review used different techniques to increase the soluble bioavailability of the product. Presently, none of the methods used has been established as being most potent for increasing the product bioavailability and this may also have accounted for the heterogeneity observed in some of the analyses; indeed, the investigators in one study 44 reported that their curcumin formulation had greater bioavailability than other types. In an RCT involving healthy volunteers, 58 curcumin formulation with a hydrophilic carrier with cellulose was shown to significantly increase bioavailability compared with other conventional formulations (none of the included studies reported using this method). Therefore, the extent to which the discrepancies in the manufacturing techniques influenced the direction of the study results in our review is uncertain. Furthermore, turmeric has for long been consumed as part of normal diet (food flavoring) in Asia, 59 but none of the studies included in our review controlled for dietary consumption among their trial participants. Whether this is due to the poor bioavailability of the product in its natural form is unclear.
There is increasing evidence to suggest that there are several phenotypes of OA 60 and the type of phenotype may determine future clinical outcomes. 61 Because curcuminoids exert their anti-inflammatory effects by modulating nuclear factor-kappa B and other cell signalling pathways, 62,63 they may possibly be more effective in the management of the more inflammatory forms of OA. However, this warrants further research.
That all the studies to date have been conducted in Asia is likely due to the fact that turmeric is native to this geographical region and has been used for treating different medical conditions over the last few centuries. 59 Furthermore, because the population in this region is an ageing population and access to conventional management strategies of severe OA such as joint replacement surgery is limited, 64 research into alternative forms of treatment may have been a priority.
Strengths and limitations
This systematic review has strengths. We employed a robust search to identify relevant studies and accounted for the quality of included RCTs. Most of our sensitivity analyses were also consistent with overall analyses. However, we recognize some limitations. We may not have identified all RCTs examining the effectiveness of curcuminoids in OA, especially unpublished studies; indeed we could not use a funnel plot to test for publication bias due to the small number of RCTs included and we could not explore dose-effect relationships for most of the outcomes assessed. We were also unable to conduct subgroup analyses based on participant demographics, and the small number of included studies prevented us from conducting further sensitivity analyses based on risk of bias or curcuminoid formulation. In addition, the results of the review are only applicable to knee OA. Furthermore, all RCTs to date have been conducted in Asian populations; therefore, the effectiveness of curcuminoids in persons of non-Asian descent is unknown.
Implications for research
High-quality clinical trials examining the effects of curcuminoids (especially in non-Asian populations) should be conducted. Such trials should last at least 3 months, as this will enable evaluation of the intermediate to long-term effects of curcuminoids in OA. Further research to assess whether using curcuminoids as adjuncts to conventional therapy can improve patientrelevant outcomes in OA should be a priority; such trials should be reported in accordance with standardized guidelines,for example, CONSORT. 65 In addition, clinical trials involving curcuminoid use in patients with OA of other joints should also be conducted to examine whether the curcuminoids have effects similar to those observed in knee OA. Further research should aim to determine the minimum effective dose based on extraction technique (and improved bioavailability) at which curcuminoids exert pharmacologic effects in OA. Future research should also incorporate the development and use of objective measures for assessing OA outcomes.
Implications for practice
Curcuminoids have some beneficial effects on pain, function and QoL in knee OA; however, they are not as effective as ibuprofen in relieving pain. Curcuminoids have no effect on knee stiffness, but their intake may reduce the need for concomitant medication. Curcuminoids should not be used as a substitute for current management of OA. Short-term consumption of curcuminoids appears to be free of serious unwanted effects; however, its intermediate to long-term safety is unknown.
CONCLUSIONS
The evidence from published RCTs suggest that compared with placebo, curcuminoids may have beneficial effects on pain and QoL in patients with knee OA. Curcuminoids have no effect on stiffness in knee OA, and are less effective than ibuprofen at alleviating pain. The curuminoids appear safe when consumed in the shortterm, but their long-term safety is uncertain. Few clinical trials assessing the effects of curcuminoids have been published. They vary in reporting quality, have small sample sizes and are confined to Asian populations. Further research investigating the effectiveness of curcuminoids in the management of OA is warranted. Figure S1 . Dose-effect plot for the curcuminoids on pain (VAS scores) in patients with knee osteoarthritis in five RCTs. Figure S2 . Effect of curcuminoids on WOMAC stiffness scores in patients with knee osteoarthritis. Figure S3 . Effect of curcuminoids on use of rescure medication in patients with knee osteoarthritis. Table S1 . Baseline demographics, components of outcomes measures, and individual results for RCTs assessing the effect of curcuminoids. Appendix S1. Search Strategies.
